PURPOSE: The impact of chemotherapeutic sequelae on long-term quality of life (QoL) for survivors of @entity5 ( @entity44 ) is unknown. The incidence of @entity137 in @entity1 treated for malignant @entity44 and possible effects on the QoL were analyzed. METHODS: Retrospective chart review of @entity1 >= 18  years treated for @entity44 in the Netherlands was performed. Present QoL was evaluated using the SF-36 questionnaire. The results of survivors of malignant @entity44 were compared to those of @entity1 treated for benign @entity44 . RESULTS: Fifty-one of 76 traceable @entity1 consented to participate. The results of 47 (92.2  %), 9 @entity1 and 38 @entity1 (median age 25.4  years, range 18.3-41.2), were analyzed. Eleven had been treated for @entity5 ; 63.6  % suffered from at least one chemotherapeutic sequel with @entity393 as the most common one. Results for both groups were similar on all but one SF-36 subcategory; those treated for @entity5 scored significantly lower on the subcategory physical functioning (p  =  0.02). CONCLUSION: Despite the high incidence of chemotherapeutic sequelae among survivors of malignant @entity44 , their QoL does not differ from that of those treated for benign @entity44 . Even though their physical functioning is restricted, daily activities and psychosocial functioning of survivors of malignant @entity44 are not restricted.

Evaluation of chemotherapeutic sequelae and quality of life in survivors of XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['chemotherapeutic toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant sacrococcygeal teratoma', 'malignant tumor', 'malignancy'] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss'] @entity44 :: ('MESH:D013724', 'Disease') :: ['SCT']
@entity5 :: (MESH:D009369,Disease) :: ['malignant sacrococcygeal teratoma']
